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Valeriana  wallichii  DC.,  Caprifoliaceae,  is used  to have  anti-ulcer,  anti-spasmodic,  anti-epileptic,  mem-
ory enhancer,  anti-anxiety,  anti-rheumatic,  sedative,  anti-asthmatic  and diuretic  activities.  V. wallichii  is
reported  to contain  valpotriates,  valeric  acid,  valerenic  acid,  valechlorine,  valerianine,  resins  and  alka-
loids.  Valeric  acid,  found  in  V.  wallichii  appears  similar  in  structure  to  the  neurotransmitter  GABA.  Valeric
acid  also  acts as  an  NMDA-receptor  antagonist.  The  aim  of present  study  was  to investigate  the neuropro-
tective  effect  of  V.  wallichii  containing  valeric  acid and its  possible  mechanism  of action  in amelioration
of  intracerebroventricular  streptozotocin  induced  neurodegeneration  in Wistar  rats.  The  rhizomes  of V.
wallichii  were powdered  coarsely  and  extracted  by percolation  method  using  dichloromethane.  Wistar
rats (220–250  g)  of either  sex were  divided  into  5  groups,  comprising  6 animals  each.  Valeric  acid  was
isolated  from  plant  extract  and  characterized  using  FT-IR.  Picrotoxin  (2 mg/kg)  was  used as  GABA-A
antagonist.  Intracerebroventricular  streptozotocin  administration  caused  signiﬁcant  (p < 0.05)  increase
in escape  latency,  retention  transfer  latency  on morris  water  maze  on  17th, 18th, 19th and  20th day  and  ele-
vated  plus  maze  on 19th and  20th day  respectively,  as  compared  to normal  untreated  rats.  Treatment  with
V.  wallichii  extract  100  and  200  mg/kg  and  valeric  acid 20 and  40  mg/kg  signiﬁcantly  decreased  the escape
latency  and  retention  transfer  latency,  as compared  to intracerebroventricular-streptozotocin  group.
Plant extract  and  valeric  acid  also  decreased  the  level  of  lipid  peroxidation  and  restored  glutathione  level
in rat  brains.  Administration  of picrotoxin  signiﬁcantly  reversed  the  effects  produced  by  plant  extract  and
valeric  acid  in intracerebroventricular-streptozotocin  treated  rats.  The ﬁndings  may  conclude  that  valeric
acid present  in  V.  wallichii  has  signiﬁcant  GABAergic  effect  in  amelioration  of  experimental  dementia.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Dementia is a clinical syndrome which is due to degeneration
f neurons in brain and spinal cord. It is associated with dete-
ioration in cognitive ability and capacity for independent living
Fratiglioni et al., 2007). The prevalence of neurodegenerative dis-
rders like Alzheimer’s diseases (AD) has increased signiﬁcantly as
lobal population age (Chen and Zheng, 2012). Currently, the num-
er of deaths caused by AD is severely high and projected to rise
y 21.2 million in 2025 (Hirtz et al., 2007; Katzman, 2008). The
haracteristic feature of AD is vascular dementia, fronto-temporal
ementia, and aggregation of amyloid, accumulation of neuroﬁb-
illary tangles, lewis body formation and neuronal death. There
s the development of multiple cognitive deﬁcits such as dis-
urbances in executive functioning, apraxia, agnosia, aphasia and
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reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
memory impairment (Fratiglioni et al., 2007) that interferes with
daily social and professional brain outcomes. The most common
symptoms of dementia are psychosis, aggression, insomnia, anxi-
ety, depression, delirium, anger and sundowning (confusion in late
afternoon or early evening) (Kuller and Lopez, 2008). The treat-
ment of AD includes acetylcholinesterase inhibitor like Tacrine,
Donepezil, Rivastigmine and Galantamine (Pokorski, 2002). More-
over, Food and Drug Administration has warned not to use atypical
antipsychotics due to their increased mortality risk (Schneider
et al., 2005).
AD is characterized by accumulation of amyloid beta peptide
(A) as ﬁbrillary plaques and soluble oligomers in brain regions
(Cole and Vassar, 2007). Tau protein is also identiﬁed as one of
the main component of neuroﬁbrillary tangles in various neuro-
logical diseases (Gendron and Petrucelli, 2009). In many areas of
CNS, overactivation of NMDAR and subsequent inﬂux or release
of excessive Ca2+ has been noted to be predominant form of
neurotoxicity. Ca2+ overload could ultimately lead to production
of reactive oxygen species (ROS) and nitric oxide (NO) radicals,
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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itochondrial dysfunction, neuronal excitotoxicity and ultimately
euronal degeneration (Majdi and Chen, 2009). Recent researches
ave emerged with evidences that some pathogenic receptors are
ltered with lower levels of GABAAR-subunits 1, 2, 4, , and
2, mRNA in prefrontal cortex and 1, 5, and 3 mRNAs in hip-
ocampus were observed in AD (Rissman and Mobley, 2011).
Valeriana wallichii DC., Capriﬁoliaceae, is found abundantly at
n altitude of 1300–3800 m in temperate Himalayas from Kash-
ir  to and between 1250 and 1800 m in Khasi hills (Chauhan,
006). It has got considerable reputation for its traditional use in
ain (Vohora and Dandiya, 1992), epilepsy, insomnia, neurosis, sci-
tica (Nadkarni, 1976; Marder et al.,  2003). The plant is widely
sed in the treatment of anxiety and depression (Panijel, 1985;
on et al.,  2000). It has been used as sedative in the treatment
f insomnia and restlessness (Leathwood and Chauffard, 1985).
aleriana is reported to have antidepressant, anxiolytic, antispas-
odic, anti-inﬂammatory and anticonvulsant activities (Sah et al.,
010). Valeric acid (VA) or pentanoic acid, a chief constituent of V.
allichii (Kokate et al., 2007), is a straight chain alkyl carboxylic
cid with chemical formula C5H10O2, molecular weight 102.15
nd melting point: 34.5 ◦C. VA appears similar in structure to the
eurotransmitter GABA but lacks amine functional group which
ontributes for the biological activities of GABA. It is reported as
ABA-A agonist and is a very good relaxant. It also acts as an NMDA-
eceptor antagonist and showed anti-epileptic effect (Loeb et al.,
990). GABA-mediated postsynaptic inhibition in cultured mam-
alian neurons was observed on treatment with VA. It increases
vailability of synaptic GABA and/or enhances postsynaptic GABA
esponses, and thus enhances GABAergic activity. Keeping this in
iew, the present study was hypothesized to investigate GABAer-
ic effect of VA from V. wallichii in amelioration of experimental
ementia in intracerebroventricular streptozotocin model in rat
rain.
aterials and methods
ollection and authentication of plant materials
The rhizomes of Valeriana wallichii DC., Capriﬁoliaceae, were col-
ected from Kufri, Shimla, HP and duly taxonomically authenticated
y Dr. R. Raina, Senior Scientist, Professor (Medicinal Plants), Dr.
.S. Parmar University of Horticulture and Forestry, Nauni, Solan,
P, India and the sample was linked to UHF-Herbarium with ﬁeld
ook number 12425.
nimals
Wistar Albino rats weighing 200–250 g of either sex were
btained from animal house (Reg No. 1541/PO/a/11/CPCSEA),
hoolini University, Solan, HP, India. The animals were allowed to
cclimatize to the environment for 7 days prior to the experimental
ession. The animals were divided into different groups consist of
ix animals (n = 6) in each group. The study was conducted as per
he guidelines of Committee for the purpose of control and supervi-
ion of experiments on animals (CPCSEA). The experimental study
as duly been approved by Institutional Animal Ethical Commit-
ee (IAEC) vide protocol no. IACE/SU-PHARM/2/020. The animals
ere maintained at standard food pellet diet from Ashirwad Indus-
ries, Chandigarh, India, water ad libitum, temperature 25 ± 2 ◦C
nd humidity 45 ± 5%.
xtraction of plant materialDried powdered rhizomes of V. wallichii (500 g) were taken
nd extracted by percolation method using dichloromethane as
olvent. The powdered material was moistened with 150 ml  of Farmacognosia 26 (2016) 484–489 485
dichloromethane and allowed to stand for approximately 4 h in
percolator. After completion of 4 h, 200 ml  of dichloromethane was
again added to form a shallow layer above the mass, and the mix-
ture was allowed to macerate in closed percolator for 24 h. The
outlet of percolator was  opened after 24 h and the liquid contained
therein was  allowed to drip slowly. Additional dichloromethane
was added until the percolate measures about three-quarters of
required volume of ﬁnished product. After completion of extrac-
tion, solvent was  then recovered and dried in rotary vacuum
evaporator.
Isolation of valeric acid
The extract of V. wallichii was  treated with methanol and sodium
bicarbonate, which produces effervescence. Then extract solution
was centrifuged, supernatant was separated and the solid mass was
dissolved in water. It was  completely dissolved in water by stir
continuously and dilute hydrochloric acid was  added dropwise to
maintain pH 2. The extraction was done three to four times with
methylene chloride in a separating funnel, concentrated the solu-
tion and thus obtained product was  subjected to characterization
(Houghton, 1988; Barnes, 2002; Gruenwald, 2004).
Fingerprint analysis of valeric acid
The ﬁngerprint analysis of isolated VA in reference to
standard sample was  done using Agilent Technologies Cary 630
Fourier transform infrared spectrophotometry (FTIR) at range
4000–650 cm−1.
Intracerebroventricular (ICV) administration of streptozotocin
(STZ) for dementia
Rats were anaesthesized using ketamine hydrochloride
(70 mg/kg i.p.)  and xylazine (5 mg/kg, i.p.). The head of the animal
was positioned in stereotaxic apparatus and a midline sagittal
incision was made in the scalp. Two holes were drilled through the
skull for placement of infusion cannula into lateral cerebral ven-
tricles with the coordinates: 0.8 mm posterior to bregma; 1.5 mm
lateral to saggital suture; 3.6 mm ventrally from the surface of the
brain and the tooth bar was set at 0 mm.  A Hamilton® syringe of
10 l was  attached through a skull hole to a stereotaxic apparatus
and piston of the syringe was lowered manually into each lateral
ventricle. STZ (3 mg/kg in two  divided doses) dissolved in citrate
buffer, pH 4.4, was  slowly infused through intracerebroventricular
route bilaterally (Tiwari et al., 2009). After ICV administration,
the cut skin was  sutured and the postoperative care were duly be
made by applying povidone–iodine solution on wound.
The behavioral assessments were done using morris water maze
test on 17th, 18th, 19th and 20th day and elevated plus maze on
19th and 20th day. On completion of protocol, the animals were
sacriﬁced and brain was isolated.
Drug administration
The plant extract of V. wallichii was  used in the dose range
from 50 to 400 mg/kg in various investigations using rats (Subhan
et al., 2009). Therefore, 100 and 200 mg/kg were selected as its
submaximal dose to investigate the biological potential against
experimentally induced neurodegeneration. The dosage of VA
selected was 20 and 40 mg/kg due to its protective action against
various experimental diseased conditions in rats (Loeb et al., 1990).
V. wallichii extract 100 and 200 mg/kg, p.o. (suspended in 1% CMC
solution) and valeric acid 20 and 40 mg/kg, i.p. (suspended in 1%
Tween 80 solution) were given to animals treated with ICV-STZ
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rom day 3rd to 21st days once daily. Picrotoxin (2 mg/kg, i.p., sus-
ended in 1% Tween 80 solution) was given as GABA-A antagonist
Sattigeri et al., 2012) 30 min  before valeric acid administration
aily.
orris water maze test
The morris water maze test was conducted for assessment of
ontextual/spatial memory in a cylindrical pool 120 cm in diameter
nd 60 cm in depth, ﬁlled with water (maintained at 28 ± 2 ◦C and
ade opaque using non-toxic paint) to a depth of 40 cm.  A circular
latform of 9 cm diameter and 38 cm height was placed in water
ank 2 cm below the water level for maze acquisition test. The pool
s divided in four equal quadrants and a platform is located in the
enter of target quadrant. The platform remains in the same posi-
ion during the training. The pool was placed in a large room, the
isible cues were provided for development of special memory and
emain unchanged throughout the study. Animals were received
our daily consecutive training sessions from 17th day to 20th day.
n each trial, animal was dropped in water facing its head toward
he wall, subjected to swim and the latency to ﬁnd the platform
as recorded up to the maximum of 2 min. The animals reached
o the platform were allowed to remain there for 20 s before next
rial. The time taken by a rat to reach the platform was  recorded as
scape latency (EL) from water (Sachdeva et al., 2014; Yang et al.,
014).
levated plus maze test
An elevated plus-maze was used to test the cognitive function
f animals. Elevated plus-maze consists of two opposite open arms
50 cm × 10 cm), crossed with two closed arms of the same dimen-
ions with 40 cm high walls. The arms were connected by a central
quare (10 cm × 10 cm)  and the apparatus was elevated 70 cm from
he ﬂoor. On day 19th and 20th, rats were placed individually at one
nd of the open arm, facing away from the central square. The time
aken for each rat to move from the open arm and enter into one of
he closed arms was recorded as “initial transfer latency” (ITL). The
nimal was allowed to explore the maze for 30 s after recording ITL
nd returns to its home cage. Then, 24 h after ITL, the rat was placed
gain on the open arm and the retention transfer latency (RTL) was
oted (Sachdeva et al., 2014).
issue biochemical estimations for oxidative stress
On day 21st, animals were sacriﬁced and their brains quickly
emoved, washed with ice-cold saline and stored at −80 ◦C. Brain
issue samples (striatum and cortex regions) were thawed and
omogenized with ten times (w/v) ice-cold 0.1 mol/l phosphate
uffer (pH 7.4). The homogenates were centrifuged at 15,000 × g for
0 min  and supernatant was then used to for assessment of level of
ipid peroxidation and glutathione as a marker for oxidative stress.
stimation of lipid peroxidation
The reaction mixture consists of 0.1 ml  of tissue homogenate,
.2 ml  of 8.1% sodium dodecyl sulphate (SDS), 1.5 ml  of 20% acetic
cid and 1.5 ml  of 0.8% aqueous solution of thiobarbituric acid (TBA).
he pH of 20% acetic acid was adjusted with 1 N NaOH to 3.5. The
ixture was ﬁnally made up to 4 ml  with distilled water and heated
t 95 ◦C for 60 min  on an oil bath. After cooling under tap water, 1 ml
f distilled water and 5 ml  of mixture of butanol and pyridine (15:1,
/v) was added and the mixture was shaken vigorously on a vor-
ex mixer. Then centrifugation at 2800 × g for 5 min  was  given and
bsorbance of organic layer (upper layer) was measured at 532 nm Farmacognosia 26 (2016) 484–489
using UV visible spectrophotometer. The level of lipid peroxidation
was expressed as nM/mg  tissue (Ohkawa et al., 1979).
Estimation of reduced glutathione (GSH)
The tissue homogenate was added with equal volume of 20%
trichloroacetic acid (TCA) containing 1 mM EDTA to precipitate
the tissue proteins. The mixture was  allowed to stand for 5 min
prior to centrifugation for 10 min  at 1000 × g. The supernatant
(200 l) was  mixed with 1.8 ml of Ellman’s reagent (5,5′-dithio bis-
2-nitrobenzoic acid) (0.1 mM)  prepared in 0.3 M phosphate buffer
with 1% of sodium citrate solution). The absorbance of solution was
estimated at 412 nm.  The level of GSH was  expressed as M/mg
tissue (Ellman, 1959).
Statistical analysis
All the results were expressed as mean ± standard deviation
(SD) and analyzed by one-way and two-way ANOVA followed by
Bonferroni’s multi-comparison test as post hoc test using biostati-
cal software Graph pad prism (version 5). p < 0.05 was considered
to be statistically signiﬁcant.
Results
Fingerprint analysis of valeric acid
Fingerprint analysis showed prominent peaks at 1737 cm−1 due
to stretching frequency of C O of carboxylic, at 2858, 2929 cm−1
due to C H stretching frequency of C H and a prominent peak at
12 cm−1 due to stretching of C OH of COOH, along with expected
peaks in the ﬁnger print region in direction of stretching frequency
of (CH2)n and of CH3 [e.g. 1465 cm−1] (supplementary material).
Effect of drug treatments on behavioral parameters on morris
water maze
The acquisition of memory in normal animals was found to
be increased as reﬂected by progressive and signiﬁcant (p < 0.05)
decrease in escape latencies of animals from 17th to 19th days. ICV-
STZ administration caused signiﬁcant (p < 0.05) increase in escape
latency on 18th, 19th and 20th day, respectively, as compared to
normal untreated rats. Treatment with V. wallichii extract (100 and
200 mg/kg) and VA (20 and 40 mg/kg) signiﬁcantly decreased the
time of escape latency, as compared to ICV-STZ control rats fol-
lowed on 17th, 18th, 19th and 20th day. Administration of picrotoxin
signiﬁcantly (p < 0.05) abolished the response of VA 40 mg/kg and
showed increased escape latency, as compared to VA40. The F value
for each variation factor like interaction, drug and time were found
to be 44.95, 453.3 and 3138 respectively (Fig. 1).
Effect of drug treatments on behavioral parameters on elevated
plus maze:
No signiﬁcant change has been observed on elevated plus
maze during assessment of ITL after induction with STZ. ICV STZ
(3 mg/kg) produced signiﬁcant (p < .05) increase in retention trans-
fer latency, as compared to initial transfer latency and normal
control. Treatment with V. wallichii extract 100 and 200 mg/kg, VA
20 and 40 mg/kg produced signiﬁcant (p < 0.05) decrease in reten-
tion transfer latency, as compared to ICV STZ control. The effect
produced by VA-40 (high dose) was  signiﬁcant (p < 0.05) in improv-
ing memory, as compared to V. wallichii extract. The effect produced
by administration of picrotoxin and VA-40 concomitantly was
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results: mean ± SD; (n = 6); analyzed by two  way ANOVA followed by Bonferroni’s
est  whereas ap < 0.05 vs NC, bp < 0.05 vs ICV STZ, and cp < 0.05 vs VA (40).
igniﬁcant, as compared to VA-40 and insigniﬁcant to ICV-STZ con-
rol (Fig. 2).
ffect of drug treatments on lipid peroxidation level
Induction with ICV STZ (3 mg/kg) produced signiﬁcant (p < 0.05)
ncrease in brain tissue lipid peroxidation level, as compared to nor-
al  untreated rats. However, V. wallichii extract 100 and 200 mg/kg,
A 20 and 40 mg/kg produced signiﬁcant reversal by decreasing
he level of brain lipid peroxidation, as compared to STZ control
p < 0.05). Treatment with picrotoxin (2 mg/kg) showed signiﬁcant
ncrease in lipid peroxidation reactions characterizing neurodegen-
ration, as compared to VA40 (Fig. 3).
ffect of drug treatments on tissue glutathione level:
Induction with ICV STZ caused signiﬁcant (p < 0.05) decrease in
issue GSH level, as compared to normal untreated rats. However, V.
allichii extract in doses 100 and 200 mg/kg, VA (20 and 40 mg/kg)
roduced signiﬁcant (p < 0.05) reversal in tissue GSH level, as com-
ared to ICV STZ control. The effect produced by picrotoxin was
igniﬁcant, as compared to VA 40 and showed decrease level of
educed glutathione (Fig. 4).ts: mean ± SD; (n = 6); analyzed by two way ANOVA followed by Bonferroni’s test
on 17th day and **p  < 0.05 vs normal on 18th day.
Discussion
The ﬁndings from present investigation revealed the GABAer-
gic effect of valeric acid from V. wallichii in amelioration of ICV-STZ
induced neurodegenerative dementia in rats. Extraction of dried
rhizome of V. wallichii was  done by percolation method using
dichloromethane. Valeric acid, a chief constituent present in V. wal-
lichii, identiﬁed by FT-IR and yield was found to be 0.8% w/v in
present study.
ICV-STZ administration is widely used model for speculating
the efﬁcacy of neuroprotective agents and to explore pharmaco-
logical interventions underlying neurodegeneration and memory
deﬁcits in the form of dementia as both are characterized by pro-
gressive deterioration of memory, cerebral glucose and energy
metabolism, and production of oxidative stress (Prakash et al.,
2015). STZ (3 mg/kg) was given via intracerebroventricular route
to induce neuronal damage without altering peripheral blood glu-
cose level. ICV-STZ is reported to cause an increase in tauprotein
and amyloid- in brain, thereby generating inﬂammatory reac-
tions and free radicals and ultimately results cell death, apoptosis
and diminution of learning and memory in experimental animals
(Weerateerangkull et al., 2008). The animals of both the sexes were
used in present study with an idea that the disease is prevalent in
both. The fact that estrogen is known to improve memory is taken
care by equally distributing the male and female rats in all groups,
including that of control.
The performance of animals during behavioral assessments
for spacial memory using morris water maze and for memory
cognition using elevated plus maze are well documented to
estimate extent of neuronal injury (Sachdeva et al., 2014). The
performance in normal and sham control groups were signiﬁcantly
increased as the animals showed progressive decrease in escape
latencies during assessments from 17th to 19th day. ICV-STZ
treatment to rats showed signiﬁcant increase in escape latency on
morris water maze and retention transfer latency on elevated plus
maze characterizing impairment in learning and memory due to
neurodegeneration which are in conﬁrmation to earlier literature
(Tiwari et al., 2009). This signiﬁes the increased neuronal damage,
reactive oxygen species and thereby oxidative stress, amyloid-beta
deposition and execution of inﬂammatory cascades resulting
memory deﬁcit (Yang et al., 2014). However, treatment with V.
wallichii extract 100 and 200 mg/kg and its chief constituent:
VA acid 20 and 40 mg/kg signiﬁcantly decreased RTL and escape
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Protection of human and animal subjects. The authors declareig. 4. Effect of drug treatments on tissue glutathione level: results: mean ± SD; (n
p < 0.05 vs ICV STZ, and cp < 0.05 vs VA (40).
atency, attenuated oxidative and inﬂammatory reactions and
hereby ameliorated ICV-STZ induced neurodegeneration. This
ffect of plant extract may  be due to the presence of VA. These ﬁnd-
ng were conﬁrmed by the results obtained in groups treated with
icrotoxin 2 mg/kg, a GABA-A antagonist followed by VA-40 mg/kg
dministration as it showed increased RTL and escape latency
hich inferred that blockage of GABA receptors by picrotoxin and
akes VA unable to correct ICV-STZ induced neurodegeneration
n rats and there was no improvement in memory.
The oxidative stress caused by ICV STZ administration increases
ipid peroxidation and decreases GSH level. Lipid peroxidation, a
easure of free radical generation was increased on day 21 in brain
f rats treated with ICV-STZ. Further production of free radicals
aused simultaneous decrease in glutathione levels. Glutathione
s an essential tripeptide, an antioxidant found in all animal cells.
t reacts with the free radicals, neutralize them and protect the
ells from singlet oxygen, hydroxyl radical and superoxide radical
amage. Treatment with V. wallichii extract (100 and 200 mg/kg)
nd VA (20 and 40 mg/kg) signiﬁcantly reduced lipid peroxida-
ion reactions and restored antioxidant defense system of cell. The
athophysiological processes of oxidative stress in chronic condi-
ions are linked with also attributed with the upstream regulation
f GABA in neuronal cells which was blocked by administration
f picrotoxin and hence showed increased lipid peroxidation reac-
ions and lowered glutathione in rats. The property of V. Wallichinalyzed by one way  ANOVA followed by Bonferroni’s test whereas ap < 0.05 vs NC,
for scavenging free radicals is also reported (Sudhanshu Rao et al.,
2012).
GABA is a major inhibitory neurotransmitter in mammalian
cerebral cortex. Temporal cortex is an area greatly affected by neu-
ropathic hallmarks of neurodegeneration. It decreases 13–17% of
benzodiazepine binding, which suggests that there is a decrease
of GABAARs in AD (Limon et al., 2012). VA elevates GABA levels
through the inactivation of -ketoglutarate dehydrogenase (Luder
et al., 1990). It decreases degradation of GABA mediated by GABA
transaminase and thus inhibits GABA catabolism. It enhances the
response of GABA-A receptor (Monti et al., 2009) and thus acts as
GABA-A agonist (Frumkes and Nelson, 1995). The ﬁndings from
present investigation may  conclude that V. wallichii and its con-
stituent valeric acid has signiﬁcant neuroprotective potential to
ameliorate memory cognition and retention possibly through GABA
receptor modulation in rats.
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